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the tissue factor (TF) extrinsic pathway acts as 
the principal regulator of coagulation.11 Physio‑
logically, TF is not expressed, or is only minimal‑
ly expressed, by endothelial cells. The situation 
changes when an inflammatory condition associ‑
ated with the production of various cytokines and 
inflammatory mediators stimulates TF expres‑
sion. TFPI is synthesized by endothelial cells.12 
Here, we measured total and free TFPI levels in 
patients with IBD to explore whether such levels 
reflected disease activity or the development of 
clinical complications.
PATIENTS AND METHODS A total of 100 patients 
with IBD aged 18 to 75 years were prospective‑
ly enrolled to the study. The study population in‑
cluded 50 consecutive patients with Crohn disease 
(CD; mean [SD] age, 34.6 [10.9] years; 22 men) 
INTRODUCTION The etiologies of inflammatory 
bowel diseases (IBDs) and associated thromboem‑
bolic complications remain poorly understood.1-4 
The possible involvement of endothelial dysfunc‑
tion has been suggested.5,6 Endothelial function 
is activated in numerous inflammatory diseases 
associated with structural and functional chang‑
es of the vascular endothelium.6,7 This endothe‑
lium is the principal effector of the inflammato‑
ry response, and it activates the coagulation cas‑
cade.8 The activated endothelium releases signif‑
icant procoagulant and anticoagulant agents, in‑
cluding von Willebrand factor (vWF) and tissue 
factor pathway inhibitor (TFPI).9 The following 
anticoagulation mechanisms control blood clot‑
ting: the heparin ‑antithrombin pathway, pro‑
tein C anticoagulant pathway, and TFPI path‑
way.10 A recent cell ‑based model suggested that 
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ABSTRACT
INTRODUCTION Endothelial dysfunction has been reported to be involved in the pathogenesis of inflam‑
matory bowel disease (IBD) and concomitant thromboembolic complications. Inflammation stimulates 
the expression of tissue factor and tissue factor pathway inhibitor (TFPI) by endothelial cells.
OBJECTIVES This study assessed the relationship between TFPI levels and disease activity in patients 
with IBD.
PATIENTS AND METHODS A total of 50 consecutive adult patients with ulcerative colitis (UC), 50 patients 
with Crohn disease (CD), and 50 healthy controls were enrolled to the study. Plasma levels of total TFPI, 
free TFPI, and von Willebrand factor were measured. Associations among these levels, disease activity, 
and inflammatory marker levels were assessed.
RESULTS Total TFPI levels were higher in patients with IBD (median, 68.5 [IQR, 60.2–80.1] ng/ml) than 
in controls (median, 61.1 ng/ml [IQR, 54.3–74.2]; P = 0.01). Free TFPI levels were higher in patients with 
active UC (median, 12.8 ng/ml [IQR, 11.1–15.4]), inactive UC (median, 9.9 ng/ml [IQR, 7.3–11.5]), active 
CD (median, 11.7 [IQR, 9.7–14.4] ng/ml), and inactive CD (median, 9.7 ng/ml [IQR, 8.6–11.6]) than in 
controls (median, 5.5 ng/ml [IQR, 4.3–7.2]; P <0.001). In the CD and UC groups, free TFPI levels correlated 
with the levels of inflammatory markers and disease activity. The von Willebrand factor level was higher 
in patients with UC (median, 143.4 IU/dl [IQR, 115.5–170.4]) and those with CD (median, 151.8 IU/dl 
[IQR, 112.8–189.4]) than in controls (85.1 IU/dl [IQR, 77.1–101.5]; P <0.001 for both comparisons).
CONCLUSIONS The anticoagulant TFPI pathway is activated during remissions and flares in patients 
with IBD. The free TFPI level correlates with biochemical markers of inflammation and disease activity.
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and continuous variables that were not normally 
distributed, as medians with interquartile ranges 
(IQRs). The Shapiro–Wilk test was used to assess 
the normality of the data distribution. The anal‑
ysis of variance or Kruskal–Wallis test was used 
to compare continuous variables. Categorical 
variables were analysed using the χ2 test. The re‑
lationships between clinical data, IBD activity, 
and biochemical parameters were assessed using 
the Spearman rank correlation coefficient. P val‑
ues of less than 0.05 were considered significant.
RESULTS Patient characteristics The demo‑
graphic, clinical, and laboratory data are sum‑
marized in TABLE 1. Patients with UC received 
mesalamine (2–4  g/d); 8 patients were on 
maintenance therapy with thiopurines. All pa‑
tients with CD were on maintenance thiopu‑
rine therapy, and those with inflammatory le‑
sions of the large intestine received mesalamine 
(2–4 g/d). No patient had undergone surgery to 
treat IBD. The mean (SD) DAI score of patients 
with inactive UC was 1.32 (1.2) points, and that 
of patients with active disease was 7.64 (2.0) 
points (P <0.001). Most patients (61%) present‑
ed moderate disease activity, 1 showed severe 
activity, and the remaining 36% had mild UC. 
The mean (SD) CDAI score of patients with in‑
active CD was 73.9 (39) points, and that of pa‑
tients with active disease was 291.6 (85.7) points 
(P <0.001). Most patients (60%) showed moder‑
ate disease activity, 1 had severe exacerbation, 
and the remaining 33% had mild CD. Higher lev‑
els of inflammatory markers (CRP and fibrino‑
gen levels, and the PLT count) were reported in 
patients with active disease as compared with 
those with inactive disease and with controls. 
In the CD group, 4 patients had hypertension; 
2, hypercholesterolemia; 2, gastroesophageal re‑
flux disease; and 2 women had hypothyroidism. 
In the UC group, 6 patients had diagnosed hy‑
pertension; 3, hypercholesterolemia; 4, gastro‑
esophageal reflux disease; and 2 hypothyroid‑
ism. These patients were on maintenance ther‑
apy with antihypertensive drugs, statins, pro‑
ton pump inhibitors, and levothyroxine substi‑
tution, respectively.
There were no differences in total TFPI, free 
TFPI, or vWF levels according to sex, age, disease 
duration, or smoking status.
Levels of total and free tissue factor pathway inhib-
itor The median total TFPI level was higher in 
patients than in controls (P = 0.01). Total TFPI 
levels did not differ between patients with UC 
and those with CD. The median free TFPI lev‑
el was significantly higher in patients with IBD 
than in controls (TABLE 1). The TFPI level differed 
between patients with active and inactive IBD 
(median [IQR], 12.43 ng/ml [9.72–14.8] and 
9.8 ng/ml [8.2–11.5], respectively; P <0.001). 
Free TFPI levels were higher in patients with 
active and inactive UC and CD than in controls 
(TABLES 2 and 3).
and 50 consecutive patients with ulcerative colitis 
(UC; mean [SD] age, 37.6 [11.2] years; 26 men). 
Patients were recruited from the Outpatient Clin‑
ic of the Gastroenterology and Hepatology Divi‑
sion of the University Hospital in Krakow, from 
October 2010 to December 2011. The diagnosis 
of IBD was based on clinical, radiological, endo‑
scopic, and histopathological criteria.13 Disease 
activity was assessed using the Crohn’s Disease 
Activity Index (CDAI) in patients with CD and 
the Disease Activity Index (DAI) in patients with 
UC.14,15 Complications were defined as abscesses, 
stenosis ‑triggering postobstructive symptoms, 
and fistulas. Based on the 2 scores, the study pop‑
ulation was divided into subgroups of patients 
with inactive CD (CDAI score <150), active CD 
(CDAI score ≥150), inactive UC (DAI score <4), 
and active UC (DAI score ≥4). 
The exclusion criteria were pregnancy, any con‑
comitant inflammatory or hematological disor‑
der, any concomitant severe disease or malig‑
nancy, any history of a thromboembolic event, 
and any history of corticosteroid use in the pre‑
vious 3 months. 
The control group consisted of 50 healthy 
volunteers (mean [SD] age, 36.7 [12.1] years; 
27 men). The study was performed in accor‑
dance with all relevant ethical principles of 
the Helsinki Declaration. Informed consent 
was obtained from all participants. The proto‑
col was approved by the Bioethics Committee 
of the Jagiellonian University of Krakow, Poland 
(KBET/161/B/2010).
We collected data on patient history, demo‑
graphic characteristics, clinical features, con‑
comitant diseases, current treatments, loca‑
tion of IBD inflammatory changes, and body 
mass index. Blood samples were collected af‑
ter an overnight fast, and the following labora‑
tory parameters were determined on the same 
day: hematocrit, white blood cell count, plate‑
let (PLT) count, C ‑reactive protein (CRP) lev‑
el, activated partial thromboplastin time, pro‑
thrombin time, and fibrinogen level. C ‑reactive 
protein was assayed using a Modular P analyz‑
er (Roche Diagnostics, Mannheim, Germany). 
Complete blood counts were performed using 
a Sysmex XE ‑2100 automated analyzer (Sys‑
mex, Kobe, Japan). The fibrinogen level, activat‑
ed partial thromboplastin time, and prothrom‑
bin time were measured using a Behring Coag‑
ulation System (Dade Behring, Marburg, Ger‑
many). The levels of vWF were measured using 
a latex immunoassay on a STAR device (Diag‑
nostica Stago, Asnieres, France) with a detec‑
tion limit of 2 IU/dl. The levels of total and free 
TFPI were measured using a latex immunoassay 
on a STAR device (Diagnostica Stago).
Statistical analysis All statistical analyses were 
performed with the Statistica software 12.0 (Stat‑
Soft Inc., Tulsa, Oklahoma, United States). Cate‑
gorical variables were expressed as percentages, 
normally distributed variables as means with SD, 
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correlated with disease activity in patients with 
CD and those with UC (r = 0.29; P = 0.04 and 
r = 0.5; P <0.001, respectively). Patients with CD 
complications showed higher free TFPI levels 
than those with complication ‑free CD (P = 0.004).
Von Willebrand factor level The vWF level was 
higher in patients with UC and those with CD 
than in controls (P <0.001 for both groups). 
Moreover, the median vWF concentrations in 
the inactive and active UC and CD groups were 
higher than in controls (TABLES 2 and 3). In pa‑
tients with CD, the vWF level was positively cor‑
related with CD activity (r = 0.32; P = 0.02) and 
the CRP level (r = 0.42; P = 0.002). In the UC 
group, the vWF level was positively correlated 
with the PLT count (r = 0.3; P = 0.03) as well 
as the CRP (r = 0.27; P = 0.047) and fibrinogen 
(r = 0.39; P = 0.003) levels, but not with disease 
activity (r = 0.15; P >0.05).
The free TFPI levels correlated with total TFPI 
levels (r = 0.56; P <0.001) (FIGURE 1A). Free and 
total TFPI levels correlated with the vWF level 
(r = 0.41; P <0.001 and r = 0.22; P <0.001; respec‑
tively; FIGURE 1B and 1C). In terms of correlations 
with inflammatory markers, the total TFPI lev‑
el did not correlate with the CRP level (r = 0.02; 
P = 0.89 for CD; r = 0.09; P = 0.52 for UC). In 
the CD group, the total TFPI level was positive‑
ly correlated only with the PLT count (r = 0.3; 
P = 0.04), and in the UC group, it was negatively 
correlated only with the albumin level (r = –0.32; 
P = 0.02). The free TFPI level was correlated with 
the levels of the following inflammatory mark‑
ers: fibrinogen (r = 0.4, P = 0.003 for UC; r = 0.36, 
P = 0.01 for CD); CRP (r = 0.55, P <0.001 for UC; 
r = 0.45, P <0.001 for CD), PLT count (r = 0.39, 
P = 0.003 for UC; r = 0.3, P = 0.03 for CD), and 
albumin (r = –0.05, P <0.001 for UC; r = –0.45, 
P  <0.001  for CD). The  free TFPI level was 
TABLE 1 Characteristics of patients
Parameter UC (n = 50) CD (n = 50) Control group 
(n = 50)
P value Pairwise comparison
UC vs CG CD vs 
CG
UC vs 
CD
Men, n (%) 26 (52) 22 (44) 25 (50) 0.71a – – –
Age, y, mean (SD) 37.6 (11.2) 34.6 (10.9) 36.7 (12.1) 0.32b – – –
BMI, kg/m2, mean (SD) 23.1 (3.8) 21.9 (4.1) 24.0 (4.8) 0.24b – – –
Smoking, n (%) 11 (22) 9 (18) 13 (26) 0.63a – – –
Disease duration, y, median 
(IQR)
5.5 (3.0–8.0) 5.0 (3.0–8.0) – 0.36d – – –
Disease remission, n (%) 22 (44) 20 (40) NA 0.84a – – –
WBC, ×103/μl, median (IQR) 6.9 (5.6–9.5) 7.2 (6.0–8.5) 5.9 (4.8–7.1) 0.004c 0.005 0.002 0.97
Platelets, ×103/μl, mean (SD) 307 (95.0) 286 (78.5) 249 (47.0) <0.001b <0.001 0.045 0.36
Fibrinogen, g/l, median (IQR) 3.0 (1.8–4.7) 4.0 (2.1–5.2) 2.5 (2.2–2.9) 0.006c 0.26 0.01 0.65
CRP, mg/l, median (IQR) 7.2 (3.9–25.4) 24.1 (4.7–51.3) 2.4 (1.4–3.0) <0.001c <0.001 <0.001 0.61
TFPI, ng/ml, median (IQR) 68.9 (61.2–81.4) 67.9 (59.6–79.6) 61.1(54.3–74.2) 0.12c
Free TFPI, ng/ml, median (IQR) 11.4 (8.3–13.7) 10.4 (9.3–13.7) 5.5 (4.3–7.2) <0.001c <0.001 <0.001 0.98
vWF:Ag, IU/dl, median (IQR) 143.4  
(115.5–170.4)
151.8  
(112.8–189.4)
85.1 
(77.1–101.5)
<0.001c <0.001 <0.001 0.99
a χ2 test;   b Analysis of variance;   c Kruskal–Wallis test;   d Mann–Whitney test
Abbreviations: BMI, body mass index; CD, Crohn disease; CG, control group; CRP, C ‑reactive protein; IQR, interquartile range; NA, not available; TFPI, 
tissue factor pathway inhibitor; UC, ulcerative colitis; vWF:Ag, von Willebrand factor antigen; WBC, white blood cells
TABLE 2 Levels of total and free tissue factor pathway inhibitor, as well as von Willebrand factor in patients with active and inactive ulcerative 
colitis
Parameter Inactive UC 
(n = 22)
Active UC 
(n = 28)
Control group 
(n = 50)
P value Pairwise comparison
Inactive UC vs 
controls
Active UC vs 
controls
Inactive vs 
active UC
TFPI, ng/ml 67.6 (61.5–81.4) 71.2 (59.4–81.9) 61.1 (54.4–4.2) 0.08 – – –
Free TFPI, ng/ml, 9.9 (7.3–11.5) 12.8 (11.1–15.4) 5.6 (4.3–7.3) <0.001a <0.001 <0.001 0.12
vWF:Ag, IU/dl 134.9 (97.4–166.5) 150 (121.1–184.8) 85.1 (77.2–101.5) <0.001a <0.001 <0.001 0.58
Data are presented as median (IQR).
a Kruskal–Wallis test
Abbreviations: see TABLE 1
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atherosclerosis, Buerger disease, advanced malig‑
nant tumors,12 chronic obstructive pulmonary dis‑
ease, acute respiratory distress syndrome, and se‑
vere pancreatitis with organ failure.17,27,28
Bernhard et al29 assessed whether children 
with CD were at greater risk of thrombin for‑
mation. A positive correlation was shown be‑
tween pediatric CD status and the thrombin lev‑
el, but the TFPI level did not differ significantly 
between those with active and inactive disease. 
Surprisingly, the mean TFPI level was significant‑
ly lower in patients with CD than in controls.29 
Similarly, Kouhutova et al30 found no difference 
in TFPI levels between patients with IBD and 
healthy individuals, or between those with ac‑
tive and inactive disease. On the contrary, we 
found that the median total TFPI level was high‑
er in patients with IBD than in controls. Howev‑
er, we did not observe such differences between 
CD and UC groups and controls, which may re‑
sult from a small study sample. Similarly, Bern‑
hard et al29 studied a group of only 22 patients. 
At the same time, it should be emphasized that in 
our study the differences between the subgroups 
DISCUSSION To our knowledge, this study is 
the first to show that the levels of free TFPI are 
positively correlated with the disease activity and 
the levels of other inflammatory markers in pa‑
tients with UC and CD. TFPI is produced by vas‑
cular endothelial cells, megakaryocytes, platelets, 
fibroblasts, and mesangial cells.16 Most TFPI re‑
mains in the endothelium, and about 15% is re‑
leased into the blood.17 Plasma TFPI is largely 
associated with lipoproteins (80%); about 20% 
is in the (active) free form.18,19 Plasma TFPI lev‑
els correlate with low ‑density lipoprotein lev‑
els.19 Free plasma TFPI exerts an anticoagulant 
activity by inhibiting the action of the TF/fac‑
tor VIIa complex.20,21 The TFPIα isoform also in‑
hibits the action of the prothrombinase complex 
that assembles prior to thrombin formation.22 
An increase in the level of free TFPI may be at‑
tributed to vascular endothelial damage.23 Ele‑
vated free TFPI levels have been observed in pa‑
tients with various inflammatory diseases, includ‑
ing rheumatoid arthritis, sepsis, and systemic lu‑
pus erythematosus.24-26 Elevated total TFPI lev‑
els are also observed in patients with obliterative 
TABLE 3 Levels of total and free tissue factor pathway inhibitor as well as von Willebrand factor in patients with active and inactive Crohn disease
Parameter Inactive CD (n = 20) Active CD (n = 30) Control group 
(n = 50)
P value Pairwise comparison
Inactive CD 
vs controls
Active CD 
vs controls
Inactive 
vs active CD
TFPI, ng/ml 66.5 (50.6–71.7) 71.3 (60.2–83.1) 61.1 (54.4–74.2) 0.06a – – –
Free TFPI, ng/ml 9.7 (8.6–11.6) 11.7 (9.7–14.4) 5.6 (4.3–7.3) <0.001a <0.001 <0.001 0.49
vWF:Ag, IU/dl 123.6 (104.3–163.2) 172.3 (120.9–200.5) 85.1 (77.2–101.5) <0.001a <0.001 <0.001 0.63
Data are presented as median (IQR).
a Kruskal–Wallis test
Abbreviations: see TABLE 1
FIGURE 1 Correlations 
between total tissue 
factor pathway inhibitor 
(TFPI), free TFPI, and von 
Willebrand factor antigen 
(vWF:Ag) in patients 
with inflammatory bowel 
diseases: A – TFPI and 
free TFPI; B – TFPI and 
vWF:Ag; C – free TFPI 
and vWF:Ag
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Our study has certain limitations. First, our 
study groups were rather small. Second, we did 
not separately measure the levels of vWF and 
the vWF propeptide. Thus, we did not distinguish 
between acute and chronic inflammation. We also 
did not measure low ‑density lipoprotein levels, 
which might affect the total TFPI level. Finally, 
this was a case ‑control study and patients were 
not followed in terms of thromboembolic events.
This study is the first to show that the antico‑
agulant TFPI pathway is activated during remis‑
sion and flare in patients with IBD. Free TFPI lev‑
els were correlated with the levels of biochemi‑
cal markers of inflammation, and with disease 
activity.
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with active disease and controls were of border‑
line significance. This discrepancy may be attrib‑
uted to differences in the definition of IBD ex‑
acerbation, which in the study by Kouhutova et 
al30 was based only on the CRP level (>5 mg/l).
We found that the free TFPI level was signifi‑
cantly elevated in patients with active IBD and in 
those in remission compared with healthy con‑
trols. No difference was observed between those 
with active and inactive disease. The free TFPI lev‑
el was associated with the clinical activity of CD 
and correlated with the levels of objective mark‑
ers of inflammation. Previous studies have doc‑
umented correlations between TFPI levels and 
the severity of inflammation. Ohair et al25 re‑
ported a trend toward higher levels of TFPI, es‑
pecially free TFPI, in patients with septic shock 
compared with those with sepsis. He et al31 ob‑
served higher TF and TFPI levels in colon biopsy 
specimens from patients with UC compared with 
controls, perhaps indicating that TF is involved 
in the hypercoagulation and microthrombosis ev‑
ident in patients with UC. However, Reichman‑
Warmusz et al32 reported that endothelial cells in 
colon biopsy specimens from patients with newly 
diagnosed IBD revealed only weak TFPI staining.
Tissue factor pathway inhibitor is not only in‑
volved in the extrinsic coagulation pathway but 
also exerts an anti ‑inflammatory effect.33 During 
inflammation, activated endothelial cells dem‑
onstrate increased surface TFPI levels.33 TFPI 
inhibits leukocyte activation, microparticle for‑
mation in the extracellular matrix, and expres‑
sion of tumor necrosis factor α, interleukin 6, 
and interleukin 1.34 High levels of total and free 
TFPI may enhance atherosclerotic lesions in cor‑
onary vessels, perhaps explaining the relation‑
ship between IBD and cardiovascular disease.11 
We found no correlation according to sex, age, 
smoking status, or disease duration, consistent 
with the observations of Radziwon et al,35 who 
reported that TFPI concentrations in plasma sam‑
ples from 100 healthy subjects did not differ by 
age, sex, or smoking status.
Von Willebrand factor, an acute ‑phase pro‑
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endothelial dysfunction.42
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